Mitchell Capital Management Co Cut By $348,068 Its Gartner (IT) Position; ACERUS PHARMACEUTICALS COMMON SHARE (TRLPF) SI Decreased By 96.15%

March 14, 2018 - By Adrian Mccoy

Mitchell Capital Management Co decreased Gartner Inc (IT) stake by 4.44% reported in 2017Q3 SEC filing. Mitchell Capital Management Co sold 2,807 shares as Gartner Inc (IT)’s stock rose 9.97%. The Mitchell Capital Management Co holds 60,439 shares with $7.52M value, down from 63,246 last quarter. Gartner Inc now has $11.17 billion valuation. The stock decreased 1.09% or $1.355 during the last trading session, reaching $122.975. About 98,430 shares traded. Gartner, Inc. (NYSE:IT) has risen 15.57% since March 14, 2017 and is uptrending. It has underperformed by 1.13% the S&P500.

ACERUS PHARMACEUTICALS CORP COMMON SHARE (OTCMKTS:TRLPF) had a decrease of 96.15% in short interest. TRLPF’s SI was 100 shares in March as released by FINRA. Its down 96.15% from 2,600 shares previously. It closed at $0.2034 lastly. It is down 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Since February 22, 2018, it had 0 insider purchases, and 4 selling transactions for $3.79 million activity. 5,713 Gartner, Inc. (NYSE:IT) shares with value of $663,566 were sold by Kranich Robin B. $664,174 worth of Gartner, Inc. (NYSE:IT) shares were sold by Sondergaard Peter. HALL EUGENE A sold $1.86M worth of Gartner, Inc. (NYSE:IT) on Monday, February 26.

Investors sentiment increased to 1.22 in Q3 2017. Its up 0.05, from 1.17 in 2017Q2. It increased, as 26 investors sold IT shares while 114 reduced holdings. 39 funds opened positions while 125 raised stakes. 85.00 million shares or 4.01% more from 81.72 million shares in 2017Q2 were reported. Cleararc Cap holds 0.04% in Gartner, Inc. (NYSE:IT) or 2,308 shares. Jefferies Grp accumulated 0% or 3,515 shares. Columbia Wanger Asset Mngmt Ltd invested in 439,622 shares or 0.81% of the stock. Legacy Private Trust Company invested in 7,120 shares or 0.11% of the stock. Vident Invest Advisory Ltd Liability Company reported 3,723 shares. Connable Office holds 2,500 shares or 0.06% of its portfolio. Saturna Capital reported 181,441 shares or 0.73% of all its holdings. Deutsche Commercial Bank Ag owns 0.03% invested in Gartner, Inc. (NYSE:IT) for 380,335 shares. Tobam holds 0.13% in Gartner, Inc. (NYSE:IT) or 27,450 shares. Amalgamated Natl Bank invested 0.07% in Gartner, Inc. (NYSE:IT). Bnp Paribas Arbitrage stated it has 0.02% in Gartner, Inc. (NYSE:IT). Southeast Asset Advsr reported 0.72% of its portfolio in Gartner, Inc. (NYSE:IT). Noesis Mangement reported 1,709 shares. Blackrock Inc reported 0.04% stake. Peak6 LP owns 1,720 shares for 0% of their portfolio.

Among 13 analysts covering Gartner Inc (NYSE:IT), 9 have Buy rating, 0 Sell and 4 Hold. Therefore 69% are positive. Gartner Inc had 48 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating by Credit Suisse given on Wednesday, April 12. The company was maintained on Friday, November 6 by RBC Capital Markets. BMO Capital Markets maintained Gartner, Inc. (NYSE:IT) rating on Sunday, November 26. BMO Capital Markets has “Buy” rating and $137.0 target. The stock has “Buy” rating by RBC Capital Markets on Friday, June 9. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, January 31. The rating was maintained by Robert W. Baird on Wednesday, September 20 with “Buy”. The stock has “Buy” rating by RBC Capital Markets on Friday, January 19. The rating was maintained by Robert W. Baird with “Buy” on Monday, January 8. The firm has “Top Pick” rating given on Friday, May 5 by RBC Capital Markets. The stock of Gartner, Inc. (NYSE:IT) earned “Outperform” rating by BMO Capital Markets on Friday, January 6.

Analysts await Gartner, Inc. (NYSE:IT) to report earnings on May, 3. They expect $0.58 earnings per share, down 3.33% or $0.02 from last year’s $0.6 per share. IT’s profit will be $52.68 million for 53.01 P/E if the $0.58 EPS becomes a reality. After $1.17 actual earnings per share reported by Gartner, Inc. for the previous quarter, Wall Street now forecasts -50.43% negative EPS growth.

Acerus Pharmaceuticals Corporation focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for menÂ’s urology and womenÂ’s hormone replacement therapy, and female sexual dysfunction. The company has market cap of $43.68 million. The companyÂ’s approved products include Natesto, a bioadhesive nasal gel formulation of testosterone; and Estrace, an oral tablet for the symptomatic relief of menopausal symptoms. It currently has negative earnings. It is also developing Gynoflo for the treatment of symptoms of vaginal atrophy; and Tefina, a nasal and low-dose gel formulation of testosterone that has been completed Phase II trials for the symptoms of female sexual dysfunction.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: